Vamil Divan
Stock Analyst at Guggenheim
(4.42)
# 291
Out of 4,840 analysts
233
Total ratings
60.13%
Success rate
13.71%
Average return
Main Sectors:
Stocks Rated by Vamil Divan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Assumes: Neutral | $288 | $271.29 | +6.16% | 1 | May 20, 2025 | |
| ANIP ANI Pharmaceuticals | Reiterates: Buy | $86 | $57.42 | +49.77% | 11 | May 12, 2025 | |
| VALN Valneva SE | Maintains: Buy | $15 → $14 | $6.34 | +120.98% | 1 | May 8, 2025 | |
| ABBV AbbVie | Maintains: Buy | $214 → $216 | $183.96 | +17.42% | 25 | Apr 29, 2025 | |
| UNCY Unicycive Therapeutics | Initiates: Buy | $6 | $0.55 | +992.90% | 1 | Apr 21, 2025 | |
| MRK Merck & Co. | Reiterates: Buy | $115 | $77.71 | +47.99% | 14 | Apr 17, 2025 | |
| TVTX Travere Therapeutics | Reiterates: Buy | $47 | $15.83 | +196.90% | 8 | Apr 14, 2025 | |
| JNJ Johnson & Johnson | Reiterates: Neutral | n/a | $153.21 | - | 15 | Apr 2, 2025 | |
| ASMB Assembly Biosciences | Initiates: Buy | $31 | $13.60 | +127.92% | 1 | Mar 25, 2025 | |
| ABSI Absci | Reiterates: Buy | $10 | $2.66 | +275.94% | 3 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $23.33 | - | 22 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $59 → $61 | $19.35 | +215.25% | 5 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $101 | $67.19 | +50.32% | 6 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $14.59 | - | 5 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $0.70 | +754.46% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $20 | $6.53 | +206.28% | 9 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $26 | $0.62 | +4,084.77% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $9 | $0.77 | +1,064.29% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $1.17 | - | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $19 | $21.63 | -12.16% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $98 | $119.68 | -18.11% | 8 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $34 | $29.45 | +15.45% | 13 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $1.71 | +484.80% | 3 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $49 | $104.49 | -53.11% | 3 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $356 | $713.56 | -50.11% | 17 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $4.83 | +24.35% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $144 → $154 | $15.46 | +896.12% | 9 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $9.66 | +55.28% | 5 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $28.79 | - | 6 | Dec 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $16.92 | - | 13 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 | $3.49 | +329.80% | 4 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $58 → $61 | $46.96 | +29.90% | 8 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $103 | $0.76 | +13,445.50% | 3 | Jan 17, 2018 |
Amgen
May 20, 2025
Assumes: Neutral
Price Target: $288
Current: $271.29
Upside: +6.16%
ANI Pharmaceuticals
May 12, 2025
Reiterates: Buy
Price Target: $86
Current: $57.42
Upside: +49.77%
Valneva SE
May 8, 2025
Maintains: Buy
Price Target: $15 → $14
Current: $6.34
Upside: +120.98%
AbbVie
Apr 29, 2025
Maintains: Buy
Price Target: $214 → $216
Current: $183.96
Upside: +17.42%
Unicycive Therapeutics
Apr 21, 2025
Initiates: Buy
Price Target: $6
Current: $0.55
Upside: +992.90%
Merck & Co.
Apr 17, 2025
Reiterates: Buy
Price Target: $115
Current: $77.71
Upside: +47.99%
Travere Therapeutics
Apr 14, 2025
Reiterates: Buy
Price Target: $47
Current: $15.83
Upside: +196.90%
Johnson & Johnson
Apr 2, 2025
Reiterates: Neutral
Price Target: n/a
Current: $153.21
Upside: -
Assembly Biosciences
Mar 25, 2025
Initiates: Buy
Price Target: $31
Current: $13.60
Upside: +127.92%
Absci
Mar 20, 2025
Reiterates: Buy
Price Target: $10
Current: $2.66
Upside: +275.94%
Mar 18, 2025
Reiterates: Buy
Price Target: n/a
Current: $23.33
Upside: -
Feb 27, 2025
Maintains: Buy
Price Target: $59 → $61
Current: $19.35
Upside: +215.25%
Feb 25, 2025
Reiterates: Buy
Price Target: $101
Current: $67.19
Upside: +50.32%
Jan 17, 2025
Reiterates: Neutral
Price Target: n/a
Current: $14.59
Upside: -
Sep 10, 2024
Initiates: Buy
Price Target: $6
Current: $0.70
Upside: +754.46%
Sep 7, 2023
Maintains: Neutral
Price Target: $19 → $20
Current: $6.53
Upside: +206.28%
Jun 15, 2023
Reiterates: Buy
Price Target: $26
Current: $0.62
Upside: +4,084.77%
Apr 3, 2023
Maintains: Buy
Price Target: $8 → $9
Current: $0.77
Upside: +1,064.29%
Mar 1, 2023
Initiates: Neutral
Price Target: n/a
Current: $1.17
Upside: -
Aug 10, 2022
Maintains: Neutral
Price Target: $27 → $19
Current: $21.63
Upside: -12.16%
Aug 8, 2022
Maintains: Neutral
Price Target: $95 → $98
Current: $119.68
Upside: -18.11%
Jul 28, 2022
Maintains: Buy
Price Target: $36 → $34
Current: $29.45
Upside: +15.45%
May 25, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $1.71
Upside: +484.80%
May 3, 2022
Maintains: Buy
Price Target: $51 → $49
Current: $104.49
Upside: -53.11%
May 2, 2022
Maintains: Buy
Price Target: $315 → $356
Current: $713.56
Upside: -50.11%
Mar 16, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $4.83
Upside: +24.35%
Mar 3, 2022
Maintains: Buy
Price Target: $144 → $154
Current: $15.46
Upside: +896.12%
May 6, 2021
Upgrades: Buy
Price Target: $15
Current: $9.66
Upside: +55.28%
Dec 13, 2019
Downgrades: Neutral
Price Target: n/a
Current: $28.79
Upside: -
Jul 10, 2019
Assumes: Neutral
Price Target: n/a
Current: $16.92
Upside: -
Aug 15, 2018
Assumes: Outperform
Price Target: $15
Current: $3.49
Upside: +329.80%
Jul 27, 2018
Maintains: Neutral
Price Target: $58 → $61
Current: $46.96
Upside: +29.90%
Jan 17, 2018
Initiates: Outperform
Price Target: $103
Current: $0.76
Upside: +13,445.50%